+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia



RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia



European Journal of Pharmacology 607(1-3): 213-219



The present study, investigates the effect of RBx 6198, 2-{3-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3a, 4, 7, 7a-tetrahydro-isoindole-1, 3,-dione, a novel alpha(1)-adrenoceptor antagonist, in both in vitro and in vivo test systems. RBx 6198 is a potent (nanomolar affinity) alpha(1A)-adrenoceptor antagonist with demonstrable uroselectivity in anaesthesized dog model. In radioligand binding studies using human recombinant receptors, RBx 6198 exhibited high selectivity (approximately 50 fold) for the alpha(1A)-adrenoceptor subtype as compared to alpha(1B)-adrenoceptor subtype. In order to assess tissue selectivity, the antagonistic effect of RBx 6198 on the phenylephrine induced contractile response of isolated rat prostate, spleen and aorta was characterized. RBx 6198 was 8 fold more potent in inhibiting phenylephrine-evoked contractions of isolated tissues compared to tamsulosin. However, the compound was non-selective for alpha(1A) vs. alpha(1D)-adrenoceptor like tamsulosin. In anaesthetized beagle dogs RBx 6198 suppressed the intraurethral pressure response to phenylephrine to a greater extent than the mean arterial pressure response thereby demonstrating uroselectivity consistent with in vitro binding and functional data. RBx 6198 was 6.4 fold more uroselective as compared to tamsulosin after i.v. route dose administration. Taken together all results from preclinical studies, it is suggested that RBx 6198 is a novel alpha(1)-adrenoceptor antagonist that exhibited improved pharmacological profile over tamsulosin in both in vitro and in vivo.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333705

Download citation: RISBibTeXText

PMID: 19239913

DOI: 10.1016/j.ejphar.2009.02.026


Related references

GYKI-16084 A novel mixed postjunctional alpha1- and alpha2-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia. European Urology 36(SUPPL 1): 116, June, 1999

Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics 40(7): 289-294, 2002

Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia. British Journal of Clinical Pharmacology 49(3): 269-273, 2000

Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Bju International 97(4): 852-855, 2006

Subtype selective alpha1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia. Expert Opinion on Investigational Drugs 8(12): 2073-2094, 2001

In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia. Life Sciences 62(17-18): 1585-1589, 1998

Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. Journal of Urology 179(3): 1040-1046, 2008

Role of alpha1-adrenoceptor subtype in prostatic growth in a benign prostatic hyperplasia model rat. The Journal of Urology 179(4): 451, 2008

Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker. Hinyokika Kiyo. Acta Urologica Japonica 54(5): 341-344, 2008

A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). British Journal of Urology 80(4): 587-596, 1997

Tamsulosin The first prostate-selective alpha-1A-adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia. Drugs of Today 32(3): 259-268, 1996

Urodynamic efficacies of silodosin, a new alpha1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. European Urology Supplements 7(3): 170, 2008

Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. Urologia Internationalis 69(4): 287-292, 2002

Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourology and Urodynamics 29(4): 558-562, 2010

Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. Prostate 67(12): 1285-1292, 2007